Cost-utility analysis of Pembrolizumab compared to other alternative immunotherapy and chemotherapy treatments for patients with advanced melanoma in Iran-Reference-Cited by-同舟云学术

Cost-utility analysis of Pembrolizumab compared to other alternative immunotherapy and chemotherapy treatments for patients with advanced melanoma in Iran

Published:2023-09-27 Issue:2 Volume:24 Page:273-284
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Bashari Negin¹²,Safaei Lari Majid²,Darvishi Ali³,Daroudi Rajabali¹²

Affiliation:

1. National Center for Health Insurance Research, Tehran, Iran

2. Department of Health Management, Policy and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

3. Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Funder

Tehran University of Medical Sciences

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2023.2263164

Reference62 articles.

1. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012;Ferlay J;Int Agency Res Cancer,2020

2. Epidemiology of skin cancer;Leiter U;Sunlight, vitamin D and skin cancer,2014

3. Epidemiology of melanoma;Matthews N;Exon Publications,2017

4. Identification of Patients With Nonmelanoma Skin Cancer Using Health Maintenance Organization Claims Data

5. NCI. Surveillance Epidemiology and end results (SEER) program cancer Statistics review 1975–2013: National cancer Institute; [Available from: http://seer.cancer.gov/csr/1975_2013/.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Future of Checkpoint Inhibitors in Uveal Melanoma: A Narrative Review;Ophthalmology and Therapy;2024-03-18